Vous avez cherché: nj drug testing for probation (Espagnol - Anglais)

carcinogenicity: testing for carcinogenicity of pharmaceuticals
carcinogenicity: testing for carcinogenicity of pharmaceuticals

testing for the detection of mycoplasma contamination vich:
testing for the detection of mycoplasma contamination vich:

stability testing for variation to a marketing authorisation type ii marzo de 1997
stability testing for variation to a marketing authorisation type ii

testing for sv40 in polio virus vaccines cpmp position statement on the quality of water used in the production of vaccines for parenteral use
cpmp position statement on the quality of water used in the production of vaccines for parenteral use

cpmp/ qwp/ 576/ 96 note for guidance on stability testing for a type ii variation to a marketing authorisation
note for guidance on stability testing for a type ii variation to a marketing authorisation

título de la directrizcarcinogenicity: testing for carcinogenicity of pharmaceuticals addendum to ` dose selection for carcinogenicity studies of pharmaceuticals': addition of a limit dose and related notes of pharmaceuticals título de la directriz
title of guideline carcinogenicity: testing for carcinogenicity of pharmaceuticals addendum to ` dose selection for carcinogenicity studies of pharmaceuticals': addition of a limit dose and related notes of pharmaceuticals title of guideline

hasta el 1 de diciembre de 1998, el national institute on drug abuse (nida) había asignado el punto límite de nivel de concentración para las pruebas de orina para opiáceos a 300 ng/ml para el federal workplace drug testing program.
until december 1, 1998, the national institute on drug abuse (nida) had set the cut-off concentration level for opiate urine tests at 300 ng/ml for the federal workplace drug testing program.

risk assessment in relation to bovine spongiform encephalopathies (bse) note for guidance on the use of bovine serum in the manufacture of human biological medicinal products concept paper on the development of a cpmp note for guidance on requirements for the evaluation of new adjuvants in vaccines testing for sv40 in polio virus vaccines cpmp position statement on the quality of water used in the production of vaccines for parenteral use points to consider on quality aspects of medicinal products containing active substances produced by stable transgene experession in higher plants committee for proprietary medicinal products (cpmp) , final eu recommendations for the influenza vaccine composition for the season 2002/2003 public report on risk and regulatory assessment of lactose and other products prepared using calfrennet cpmp position statement on non-remunerated and remunerated donors:
risk assessment in relation to bovine spongiform encephalopathies (bse) concept paper on the development of a cpmp note for guidance on requirements for the evaluation of new adjuvants in vaccines testing for sv40 in polio virus vaccines cpmp position statement on the quality of water used in the production of vaccines for parenteral use committee for proprietary medicinal products (cpmp) , final eu recommendations for the influenza vaccine composition for the season 2002/2003 public report on risk and regulatory assessment of lactose and other products prepared using calfrennet cpmp position statement on non-remunerated and remunerated donors: